Hook & thesis
Perdoceo Education (PRDO) is worth a fresh look. The company has shown material revenue and profit improvement recently, generated robust free cash flow, and returned capital aggressively through buybacks. At a market capitalization of roughly $2.16 billion and trading around $34.45, PRDO is trading at a mid-teens earnings multiple that, to us, understates the sustainability of its cash generation.
We are upgrading PRDO to a Buy and recommending an actionable swing trade entry at $34.45 with a target of $40.00 and a stop at $31.50. The valuation picture - about 12-13x trailing earnings and EV/EBITDA near 8.1 - leaves upside if margins hold and growth continues. Leverage is almost non-existent and free cash flow was strong, which cushions downside and enables continued buybacks and dividends.
What the company does and why it matters
Perdoceo operates three higher-education brands: Colorado Technical University (CTU), the American InterContinental University System (AIU), and the University of St. Augustine for Health Sciences (USAHS). The business is focused on career-oriented programs - nursing and allied health, business, technology and cybersecurity, and several graduate health science programs. That mix gives Perdoceo exposure to secular demand for healthcare professionals and tech skills while keeping tuition-driven cash flows relatively stable.
The market should care because this is a cash-generative education operator with improving profitability and a management team willing to return capital. Recent reported figures show revenue growth of roughly 24% to $846 million and net income of $160 million. Free cash flow is meaningful - reported at $220.9 million - which supports buybacks (about $120.8 million recently) and a modest dividend. With debt-to-equity at roughly 0.01, the company has financial flexibility most of its peers lack.
Fundamental backdrop with numbers
- Market cap: approximately $2.16 billion and enterprise value of about $2.00 billion.
- Profitability: trailing EPS around $2.71, implying a P/E in the low-to-mid teens (roughly 12-13x at the current price).
- Cash flow: free cash flow about $220.9 million and price-to-free-cash-flow ~9.77.
- Leverage and liquidity: debt-to-equity around 0.01 and reported cash per share metrics supportive (cash appears healthy relative to liabilities).
- Dividend & buybacks: quarterly dividend of $0.15 and recent buybacks of $120.8 million indicate active capital allocation.
- Valuation multiples: EV/EBITDA ~8.13, EV/Sales ~2.35, price-to-book ~2.16.
Those numbers combine to form a straightforward investment case: solid cash flow, low leverage, and valuation that is not demanding for an established operator in vocational and healthcare education.
Technical and sentiment context
Technicals are constructive but not frothy. The stock sits above key short-term moving averages (10/20/50-day) with a 10-day SMA near $32.86, a 20-day near $33.31 and a 50-day near $33.74. RSI around 57 indicates room to run before overbought conditions, and MACD shows bullish momentum. Short interest has fluctuated but recent data show meaningful short activity and elevated short-volume on several trading days, which could accelerate moves if sentiment turns positive.
Valuation framing
At around $34.45, PRDO trades at roughly 12-13x trailing earnings and an EV/EBITDA near 8.1. For a company that converted to $220.9 million in free cash flow and reported $160 million in net income on roughly $846 million of revenue, that multiple looks reasonable and arguably conservative relative to peers that carry higher leverage or weaker cash generation. The dividend yield is modest at ~1.7%, but buybacks have been the more important capital return mechanism recently.
We are not treating PRDO as a high-growth multiple story. This is a value-oriented setup: the market is rewarding earnings accretion and de-risked balance-sheet more than top-line exuberance. If growth continues in healthcare and technology programs and margins remain elevated, the stock can re-rate to a higher multiple, especially given its near-zero leverage.
Catalysts
- Quarterly results that sustain margin expansion and free cash flow - another beat on earnings or guidance could push the stock toward the $38-$42 range.
- Continued aggressive buybacks. Management has already repurchased roughly $120.8 million; additional repurchases would accelerate EPS accretion.
- Positive industry comps or regulatory clarity that benefits private and career-focused education providers.
- Insider activity that is interpreted as confidence (or the absence of negative insider activity) could support sentiment. Note there was a recent CFO sale that management characterized as portfolio trimming after a strong run.
- Short-covering reflex. Short interest and recent high short-volume days mean a relatively small catalyst could accelerate buying if shorts cover.
Trade plan (actionable)
We recommend a staged long entry with explicit risk controls:
- Entry: Buy at $34.45. This is close to the current quote and keeps slippage low.
- Stop: $31.50. This level sits under the 50-day SMA and provides a disciplined exit if momentum reverses.
- Target: $40.00. This puts the trade above the 52-week high of $38.50 and captures a re-rating to ~15x+ earnings or multiple expansion from EV/EBITDA normalization.
Horizon and position sizing
- Short term (10 trading days): Use for a quick pop trade if catalysts arrive (earnings beat or a buyback announcement). Expect volatile intraday moves; exit if momentum fades.
- Mid term (45 trading days): Our primary recommendation falls here. A sustained re-rating to $40 is achievable within 11-45 trading days as earnings visibility improves or buyback announcements continue.
- Long term (180 trading days): Hold only if fundamentals continue to improve and management signals further capital return. Longer holds hinge on top-line stability and regulatory environment.
Position sizing should reflect the stop. From $34.45 entry to $31.50 stop is $2.95 risk per share. Choose a size that limits portfolio risk to your acceptable dollar loss per trade.
Risks and counterarguments
- Regulatory risk: Education providers are exposed to changes in federal financial aid policy and accreditation standards. A negative regulatory shift could pressure enrollments and margins.
- Enrollment volatility: Enrollment trends can swing with macro conditions. A deterioration in enrollment at CTU, AIU, or USAHS would compress revenue growth and cash flow.
- Market multiple compression: If the market re-prices education stocks lower, even solid fundamentals may not prevent a share price decline from multiple contraction.
- Insider selling noise: While recent insider sales have been described as portfolio trimming after a +50% one-year move, continued or larger insider exits could be perceived negatively.
- Execution risk: Maintaining margin expansion and managing cost structure across three distinct brands requires execution. Any operational misstep could hurt margins.
Counterargument
Critics will argue PRDO's market is cyclical and policy-sensitive; valuation should include a regulatory discount. That’s reasonable. If you assign a higher risk premium the stock could easily trade below 10x earnings, which would put the fair value closer to $27-$30. However, the company’s low leverage, strong free cash flow and active buybacks reduce the probability of a severe downside, and recent fundamentals show real improvement rather than one-off items.
Conclusion and what will change our view
We upgrade PRDO to Buy and present a swing trade at $34.45 with a $40.00 target and a $31.50 stop. The combination of solid earnings, $220.9 million in free cash flow, near-zero leverage and active capital returns creates an attractive risk-reward for the next 11-45 trading days. The trade relies on continued margin stability and either buyback momentum or positive earnings/guidance.
What would change our mind?
- Worsening enrollment trends across core segments or an earnings miss that lowers free cash flow materially would prompt a downgrade.
- Any evidence that buybacks are being curtailed or that management shifts to a more conservative cash profile would reduce the attractiveness of the trade.
- A meaningful regulatory shift that threatens federal aid access or accreditation status would shift our view decisively negative.
For now, Perdoceo looks like an underappreciated cash engine in the vocational and healthcare education space. We prefer buying into stability and cash generation at a reasonable multiple rather than paying up for uncertain growth. That practical trade is what motivates our upgrade and the actionable entry/stop/target above.
Key metrics snapshot: Market cap ~$2.16B, EV ~$2.00B, trailing EPS ~$2.71, free cash flow ~$220.9M, debt-to-equity ~0.01, dividend $0.15 quarterly.